Development of a risk score to guide targeted hepatitis C testing among human immunodeficiency virus patients in Cambodia

Table 2 Characteristics of the derivation cohort, including the candidate predictors

Characteristics	Missing values	n = 3045	Candidate predictor
HIV patients with HCV coinfection, n (%)	0	106 (3.5)
Male, n (%)	0	1,307 (42.9)	√
Age, yr, median (IQR)	0	42.5 (36.3-48.1)	√
Key populations1, n (%)	0	31 (0.1)
Receiving ART, n (%)	0	2,972 (97.6)
On NNRTI-based ART, n (%)		2,728 (91.8)
On PI-based ART, n (%)		232 (7.8)
Other, n (%)		12 (0.4)
Duration on ART, years, median (IQR)	0	6.9 (4.4-9.1)
HIV viral load < 50 copies/mL, n (%)	368	2,517 (96.6)
CD4, cells/µL, median (IQR)	11	464 (339-609)
Poor CD4 recovery on ART2, n (%)	13	117 (4.0)	√
ALT, IU/L, median (IQR)	0	28 (20-43)	√
AST, IU/L, median (IQR)	0	26 (21-36)	√
Platelets, × 109 cells/L, median (IQR)	0	266 (221-312)	√
APRI, median (IQR)	0	0.29 (0.21-0.41)	√
Fatigue, myalgia/arthralgia, or anorexia/weight loss, n (%)	0	301 (9.9)	√
Diffuse pruritus, n (%)	0	120 (3.9)	√
Diabetes mellitus, n (%)	6	113 (3.7)	√
Hepatitis B surface antigen positive, n (%)	0	311 (10.2)
Partner or household member with liver disease, n (%)	10	185 (6.1)	√

¹homosexual, history or current injecting drug user, or history or currently engaged in sex work.

²CD4 below200 after 3 years or more on ART.

ART: Antiretroviral therapy; NNRTI: Non-nucleoside reverse transcriptase inhibitor; PI: Protease inhibitor; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; APRI: AST-to-platelet ratio index; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus.